FDA Advisory Committee Votes Unanimously in Favor of Expanding Amarin’s Vascepa Label

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee on Thursday voted 16-0 to recommend that the agency expand the label of Amarin’s Vascepa (icosapent ethyl), a derivative of fish oil, to add an indication on reducing the risk of cardiovascular events.